Prediction models for assessing long-term outcome in Alzheimer's disease: A review

American Journal of Alzheimer's Disease and other Dementias

Volumn 28, Issue 5, 2013, Pages 440-449

  Wattmo, Carina ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

activities of daily living; Alzheimer's disease; cognition; disease progression; longitudinal studies; statistical models

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN E4; DONEPEZIL; GALANTAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; RIVASTIGMINE;

ADL DISABILITY; ALZHEIMER DISEASE; COGNITION; DAILY LIFE ACTIVITY; EMPIRICAL RESEARCH; FUNCTIONAL ASSESSMENT; HUMAN; LONG TERM CARE; MENTAL DETERIORATION; MINI MENTAL STATE EXAMINATION; OPEN STUDY; OUTCOME ASSESSMENT; PREDICTION; REVIEW;

ACTIVITIES OF DAILY LIVING; ALZHEIMER'S DISEASE; COGNITION; DISEASE PROGRESSION; LONGITUDINAL STUDIES; STATISTICAL MODELS;

ALZHEIMER DISEASE; ANIMALS; CHOLINESTERASE INHIBITORS; HUMANS; MODELS, BIOLOGICAL; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; TIME;

EID: 84881465004     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317513488916     Document Type: Review

References (75)

1. Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging. 2006 ; 10 (5). 417-429
2. Stern Y, Liu X, Albert M, et al. Application of a growth curve approach to modeling the progression of Alzheimer's disease. J Gerontol A Biol Sci Med Sci. 1996 ; 51 (4). M179 - M184
3. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968 ; 114 (512). 797-811
4. Huff FJ, Growdon JH, Corkin S, Rosen TJ. Age at onset and rate of progression of Alzheimer's disease. J Am Geriatr Soc. 1987 ; 35 (1). 27-30
5. Katzman R, Brown T, Thal LJ, et al. Comparison of rate of annual change of mental status score in four independent studies of patients with Alzheimer's disease. Ann Neurol. 1988 ; 24 (3). 384-389
6. Salmon DP, Thal LJ, Butters N, Heindel WC. Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations. Neurology. 1990 ; 40 (8). 1225-1230
7. Ortof E, Crystal HA. Rate of progression of Alzheimer's disease. J Am Geriatr Soc. 1989 ; 37 (6). 511-514
8. Yesavage JA, Brooks JO III, Taylor J, Tinklenberg J. Development of aphasia, apraxia, and agnosia and decline in Alzheimer's disease. Am J Psychiatry. 1993 ; 150 (5). 742-747
9. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 ; 12 (3). 189-198
10. Mortimer JA, Ebbitt B, Jun SP, Finch MD. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology. 1992 ; 42 (9). 1689-1696
11. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984 ; 141 (11). 1356-1364
12. Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry. 1994 ; 151 (3). 390-396
13. Morris JC, Edland S, Clark C, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology. 1993 ; 43 (12). 2457-2465
14. Mendiondo MS, Ashford JW, Kryscio RJ, Schmitt FA. Modelling mini mental state examination changes in Alzheimer's disease. Stat Med. 2000 ; 19 (11-12). 1607-1616
15. Teri L, McCurry SM, Edland SD, Kukull WA, Larson EB. Cognitive decline in Alzheimer's disease: a longitudinal investigation of risk factors for accelerated decline. J Gerontol A Biol Sci Med Sci. 1995 ; 50A (1). M49 - M55
16. Rasmusson DX, Carson KA, Brookmeyer R, Kawas C, Brandt J. Predicting rate of cognitive decline in probable Alzheimer's disease. Brain Cogn. 1996 ; 31 (2). 133-147
17. Galasko DR, Gould RL, Abramson IS, Salmon DP. Measuring cognitive change in a cohort of patients with Alzheimer's disease. Stat Med. 2000 ; 19 (11-12). 1421-1432
18. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982 ; 38 (4). 963-974
19. Suh GH, Ju YS, Yeon BK, Shah A. A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline. Int J Geriatr Psychiatry. 2004 ; 19 (9). 817-824
20. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008 ; 22 (3). 209-221
21. Wattmo C, Wallin AK, Londos E, Minthon L. Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment. Alzheimer Dis Assoc Disord. 2011 ; 25 (1). 63-72
22. Wattmo C, Wallin AK, Londos E, Minthon L. Predictors of long-term cognitive outcome in Alzheimer's disease. Alzheimers Res Ther. 2011 ; 3 (4). 23
23. Sabbagh MN, Farlow MR, Relkin N, Beach TG. Do cholinergic therapies have disease-modifying effects in Alzheimer's disease?. Alzheimers Dement. 2006 ; 2 (2). 118-125
24. Grossberg G, Irwin P, Satlin A, Mesenbrink P, Spiegel R. Rivastigmine in Alzheimer disease: efficacy over two years. Am J Geriatr Psychiatry. 2004 ; 12 (4). 420-431
25. Pirttila T, Wilcock G, Truyen L, Damaraju CV. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. Eur J Neurol. 2004 ; 11 (11). 734-741
26. Raskind MA, Peskind ER, Truyen L, Kershaw P, Damaraju CV. The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial. Arch Neurol. 2004 ; 61 (2). 252-256
27. Wallin AK, Andreasen N, Eriksson S, et al. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting. Dement Geriatr Cogn Disord. 2007 ; 23 (3). 150-160
28. Small GW, Kaufer D, Mendiondo MS, Quarg P, Spiegel R. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract. 2005 ; 59 (4). 473-477
29. Ashford JW, Schmitt FA. Modeling the time-course of Alzheimer dementia. Curr Psychiatry Rep. 2001 ; 3 (1). 20-28
30. Liu X, Tsai WY, Stern Y. A functional decline model for prevalent cohort data. Stat Med. 1996 ; 15 (10). 1023-1032
31. Ashford JW, Shan M, Butler S, Rajasekar A, Schmitt FA. Temporal quantification of Alzheimer's disease severity: 'time index' model. Dementia (Basel, Switzerland). 1995 ; 6 (5). 269-280
32. Wattmo C, Hansson O, Wallin AK, Londos E, Minthon L. Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting. Dement Geriatr Cogn Disord. 2008 ; 26 (3). 203-211
33. Green CR, Mohs RC, Schmeidler J, Aryan M, Davis KL. Functional decline in Alzheimer's disease: a longitudinal study. J Am Geriatr Soc. 1993 ; 41 (6). 654-661
34. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969 ; 9 (3). 179-186
35. Imbimbo BP, Verdelli G, Martelli P, Marchesini D.. Two-year treatment of Alzheimer's disease with eptastigmine. The Eptastigmine study group. Dement Geriatr Cogn Disord. 1999 ; 10 (2). 139-147
36. Han L, Cole M, Bellavance F, McCusker J, Primeau F. Tracking cognitive decline in Alzheimer's disease using the mini-mental state examination: a meta-analysis. Int Psychogeriatr. 2000 ; 12 (2). 231-247
37. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003 ; 289 (21). 2819-2826
38. Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tensfeldt T. Disease progression meta-analysis model in Alzheimer's disease. Alzheimers Dement. 2010 ; 6 (1). 39-53
39. Stern RG, Mohs RC, Bierer LM, et al. Deterioration on the blessed test in Alzheimer's disease: longitudinal data and their implications for clinical trials and identification of subtypes. Psychiatry Res. 1992 ; 42 (2). 101-110
40. Locascio JJ, Growdon JH, Corkin S. Cognitive test performance in detecting, staging, and tracking Alzheimer's disease. Arch Neurol. 1995 ; 52 (11). 1087-1099
41. Saxton J, McGonigle-Gibson KL, Swihart AA, Miller VJ, Boller F. Assessment of the severely impaired patient: description and validation of a new neuropsychological test battery. J Consult Clin Psychol. 1990 ; 2 (3). 298-303
42. Schmitt FA, Ashford W, Ernesto C, et al. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's disease cooperative study. Alzheimer Dis Assoc Disord. 1997 ; 11 (suppl 2). S51 - S56
43. Wild KV, Kaye JA. The rate of progression of Alzheimer's disease in the later stages: evidence from the Severe impairment battery. J Int Neuropsychol Soc. 1998 ; 4 (5). 512-516
44. Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther. 1999 ; 53 (5). 471-481
45. Feldman H, Sauter A, Donald A, et al. The disability assessment for dementia scale: a 12-month study of functional ability in mild to moderate severity Alzheimer disease. Alzheimer Dis Assoc Disord. 2001 ; 15 (2). 89-95
46. Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol. 2000 ; 10 (3). 195-203
47. Wallin AK, Wattmo C, Minthon L. Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting. Neuropsychiatr Dis Treat. 2011 ; 7: 565-576
48. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol. 2006 ; 63 (1). 49-54
49. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 study group. Neurology. 2000 ; 54 (12). 2261-2268
50. Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol. 2001 ; 58 (3). 427-433
51. Burns A, Gauthier S, Perdomo C. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2007 ; 22 (8). 806-812
52. Winblad B, Wimo A. Engedal K, et al. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord. 2006 ; 21 (5-6). 353-363
53. Farlow M, Anand R, Messina J, Hartman R, Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol. 2000 ; 44 (4). 236-241
54. Lenth RV. Some practical guidelines for effective sample size determination. Am Stat. 2001 ; 55 (3). 187-193
55. Pavlik VN, Doody RS. Progress in understanding variability in cognitive responses to cholinesterase inhibitor treatment. Alzheimers Res Ther. 2011 ; 3 (5). 30
56. Albert SM, Sano M, Marder K, et al. Participation in clinical trials and long-term outcomes in Alzheimer's disease. Neurology. 1997 ; 49 (1). 38-43
57. Schneider LS, Olin JT, Lyness SA, Chui HC. Eligibility of Alzheimer's disease clinic patients for clinical trials. J Am Geriatr Soc. 1997 ; 45 (8). 923-928
58. Lyle S, Grizzell M, Willmott S, Benbow S, Clark M, Jolley D. Treatment of a whole population sample of Alzheimer's disease with donepezil over a 4-year period: lessons learned. Dement Geriatr Cogn Disord. 2008 ; 25 (3). 226-231
59. Behl P, Lanctot KL, Streiner DL, Black SE. The effect of cholinesterase inhibitors on decline in multiple functional domains in Alzheimer's disease: a two-year observational study in the Sunnybrook dementia cohort. Int Psychogeriatr. 2008 ; 20 (6). 1141-1159
60. Cummings JL. What we can learn from open-label extensions of randomized clinical trials. Arch Neurol. 2006 ; 63 (1). 18-19
61. Waldemar G. Donepezil in the treatment of patients with Alzheimer's disease. Expert Rev Neurother. 2001 ; 1 (1). 11-19
62. Jones RW, Schwam E, Wilkinson D, et al. Rates of cognitive change in Alzheimer disease: observations across a decade of placebo-controlled clinical trials with donepezil. Alzheimer Dis Assoc Disord. 2009 ; 23 (4). 357-364
63. Schmeidler J, Mohs RC, Aryan M. Relationship of disease severity to decline on specific cognitive and functional measures in Alzheimer disease. Alzheimer Dis Assoc Disord. 1998 ; 12 (3). 146-151
64. Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006 ; 367 (9516). 1057-1065
65. Ferris S, Cummings J, Christensen D, et al. Effects of donepezil 23 mg on severe impairment battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity. Alzheimers Res Ther. 2013 ; 5 (1). 12
66. Hall CB, Ying J, Kuo L, Lipton RB. Bayesian and profile likelihood change point methods for modeling cognitive function over time. Comput Stat Data Anal. 2003 ; 42 (1-2). 91-109
67. Bartolucci A, Bae S, Singh K, Griffith HR. An examination of Bayesian statistical approaches to modeling change in cognitive decline in an Alzheimer's disease population. Math Comput Simul. 2009 ; 80 (3). 561-571
68. Martins CA, Oulhaj A, de Jager CA, Williams JH. APOE alleles predict the rate of cognitive decline in Alzheimer disease: a nonlinear model. Neurology. 2005 ; 65 (12). 1888-1893
69. Wilkosz PA, Seltman HJ, Devlin B, et al. Trajectories of cognitive decline in Alzheimer's disease. Int Psychogeriatr. 2010 ; 22 (2). 281-290
70. Molnar FJ, Man-Son-Hing M, Hutton B, Fergusson DA. Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review. Open Med. 2009 ; 3 (2). e31 - e50
71. Wilson RS, Beckett LA, Barnes LL, et al. Individual differences in rates of change in cognitive abilities of older persons. Psychol Aging. 2002 ; 17 (2). 179-193
72. Milliken JK, Edland SD. Mixed effect models of longitudinal Alzheimer's disease data: a cautionary note. Stat Med. 2000 ; 19 (11-12). 1617-1629
73. Brown H, Prescott R Applied Mixed Models in Medicine. 2 nd ed. Chichester, UK: Wiley; 2006. Chichester, UK: Wiley ; 2006 :
74. Locascio JJ, Atri A. An overview of longitudinal data analysis methods for neurological research. Dement Geriatr Cogn Dis Extra. 2011 ; 1 (1). 330-357
75. Rogers JA, Polhamus D, Gillespie WR, et al. Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: a beta regression meta-analysis. J Pharmacokinet Pharmacodyn. 2012 ; 39 (5). 479-498